Inactive Instrument

Vincero Capital Corp.

VCO.P

CA9273191036

Vincero Capital Corp. Reports Earnings Results for the Full Year Ended June 30, 2020

October 02, 2020 at 10:50 pm IST

Vincero Capital Corp. announced earnings results for the full year ended June 30, 2020. For the full year, the company announced net loss was CAD 190,934. Basic loss per share from continuing operations was CAD 0.1.

Latest news about Vincero Capital Corp.

Vincero Capital Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	26/22/26	CI
Vincero Capital Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	24/21/24	CI
Certain Worldwide Rights of NewGen Therapeutics, Inc. completed the acquisition of Vincero Capital Corp. (TSXV:VCO.P) in a reverse merger transaction.	25/21/25	CI
Vincero Capital Corp. Reports Earnings Results for the Second Quarter Ended December 31, 2020	26/21/26	CI
Vincero Capital Corp. Reports Earnings Results for the First Quarter Ended September 30, 2020	06/20/06	CI
Vincero Capital Corp. Reports Earnings Results for the Full Year Ended June 30, 2020	02/20/02	CI
Vincero Capital Corp. Reports Earnings Results for the Third Quarter Ended March 31, 2020	28/20/28	CI
Certain Worldwide Rights of NewGen Therapeutics, Inc. entered into a letter of intent to acquire Vincero Capital Corp. (TSXV:VCO.P) in a reverse merger transaction for CAD 6 million.	27/20/27	CI
Vincero Capital Corp. Reports Earnings Results for the Second Quarter Ended December 31, 2019	20/20/20	CI
Vincero Capital Corp. has completed an IPO in the amount of CAD 0.5 million.	07/20/07	CI
Vincero Capital Corp. Reports Earnings Results for the First Quarter Ended September 30, 2019	28/19/28	CI
Vincero Capital Corp. has filed an IPO in the amount of CAD 0.5 million.	11/19/11	CI

Chart Vincero Capital Corp.

Duration

Period

More charts

Company Profile

Rakovina Therapeutics, Inc., formerly Vincero Capital Corp., is a Canada-based company, which is engaged in developing cancer treatments based on DNA-damage response technologies. The Company's lead product candidate is kt-2000 Next Generation PARP-inhibitors. Its pipeline includes kt-3000 Dual Action DDR-inhibitors and kt-4000 DNA Damaging DDR-inhibitors. Its kt-2000 series is a patented class of highly potent, oral inhibitors of poly (ADP-ribose) polymerase (PARP). Its kt-3000 drug candidates selectively inhibit secondary DDR pathways associated with treatment resistance and PARP. kt-4000 drug candidates release a potent DNA-damaging agent, while also inhibiting DDR to selectively kill cancer cells.

Sector

Investment Holding Companies

More about the company

Sector Shell Companies

	1st Jan change	Capi.
TRUMP MEDIA & TECHNOLOGY GROUP CORP.	+76.43%	5.87B
CHURCHILL CAPITAL CORP VII	+2.76%	988M
PERELLA WEINBERG PARTNERS	+46.03%	955M
ARES ACQUISITION CORPORATION II	+2.49%	669M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
E7 GROUP	-2.15%	593M
ADMIRAL ACQUISITION LIMITED	+10.28%	536M
CAPITOL INVESTMENT CORP. VII	-.--%	500M
AEA-BRIDGES IMPACT CORP.	-2.10%	470M

Shell Companies